How excited should we be about the latest news of the Oxford vaccine? At least this time – in contrast to previous updates, which have tended to come via Downing Street briefings – we have a paper in a scientific journal, the Lancet, to go by. The paper reports that 1,077 people took part in the trial and that 90 per cent developed antibodies to the SARS-CoV-2 virus after a single dose of the vaccine.
Already a subscriber? Log in
Easter flash sale:
10 issues for $1
Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.
- Weekly delivery of the magazine
- Unlimited access to spectator.com.au and app
- Spectator Australia podcasts and newsletters
- Full access to spectator.co.uk
Or
Comments
Easter flash sale: 10 issues for $1
Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.
CLAIM OFFER 10 issues for $1Already a subscriber? Log in